{"id":"NCT00775437","sponsor":"AbbVie (prior sponsor, Abbott)","briefTitle":"Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use","officialTitle":"Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2008-10-20","resultsPosted":"2016-01-26","lastUpdate":"2016-01-26"},"enrollment":32,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Juvenile Idiopathic Arthritis"],"interventions":[{"type":"DRUG","name":"Adalimumab","otherNames":["Humira","ABT-D2E7"]}],"arms":[{"label":"Adalimumab","type":"EXPERIMENTAL"}],"summary":"The main objective of this study is to evaluate the safety of adalimumab in patients 2 to \\< 4 years of age or â‰¥ 4 years of age weighing \\< 15 kg, with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) or polyarticular course JIA.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"TEAEs were collected from first dose of study drug until 70 days after the last dose of study drug and before start of commercial adalimumab or other biologics (32.5 months).","effectByArm":[{"arm":"Adalimumab","deltaMin":29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["30054164","24487484"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":32},"commonTop":["Nasopharyngitis","Pyrexia","Cough","Rhinorrhoea","Bronchitis"]}}